Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

A>

About Vectura

Vectura Group plc is a product development company focused on the development of a range of inhaled therapies principally for the treatment of respiratory diseases. Vectura develops products to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, a market which is forecast to double over the next ten years from $23 billion in 2007 to $46 billion by 2017. Vectura also develops products for non-respiratory diseases where optimised delivery via the lungs could provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.

Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company seeks to develop certain programmes further through development to optimise value through licensing at a later stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with several pharmaceutical companies including Boehringer Ingelheim, Novartis and Sandoz. The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, GlaxoSmithKline (GSK), Merck Generics (part of Mylan Inc), UCB and Otsuka, as well as providing revenue streams, complementary products and critical mass. For further information, please visit Vectura's website at http://www.vectura.com

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's or Vectura's actual results to differ mate
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
(Date:9/18/2014)... , September 18, 2014 After ... chain community, we,re finally here - the new programme for ... January 2015, part of our global Cool Chain series, has ... here ! As the lines between supply ... put together a programme that is broad and yet specific, ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
Breaking Medicine Technology:Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Nationally-acclaimed researcher and award-winning author Dr. Cynthia ... National Conference on Cancer Nursing Research that silver treated ... were supposed to prevent. After testing ... with silver coated or silver impregnated fluid pathway components, ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced the ... shares of its common stock, offered at a price to ... Optimer from this offering are expected to be $67.5 million, ... offering expenses payable by Optimer.  The offering is expected to ...
Cached Medicine Technology:Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 3
(Date:9/19/2014)... with friends is a big part of being young, and ... look graceful without spending a large sum of money. Recently, ... prom dresses. Apart from this, it has launched a big ... all the global consumers can enjoy a discount, up to ... , The company’s chief executive officer says, “We are proud ...
(Date:9/18/2014)... Petersburg, FL (PRWEB) September 19, 2014 ... with patented ingredients made just for these issues in ... includes Matrixyl, Haloxyl and Eyeliss," says Kathy Heshelow, founder ... inflammation, improving circulation and boosting collagen, to improve the ... special eye serum for wrinkles, dark circles and ...
(Date:9/18/2014)... September 18, 2014 Active Aging Week ... older as fully participating members of society and promotes ... celebrate, The Stafford – a boutique retirement community located ... will host two screenings of Cyber-Seniors - a humorous ... our residents to watch this great film,” says Thomas ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a ... of Facial Plastic and Reconstructive Surgery and a Professor ... Facial Plastic Surgery. He is recognized around the ... , Dr. Ellis will be presenting on numerous injectable ... injection techniques and various treatments for complications associated with ...
(Date:9/18/2014)... 2014 A jacket is a hip- ... typically has sleeves, and fastens in the front or ... tighter-fitting, and less insulating than a coat, which is ... protective clothing. Today, Fecbek, a well-known clothing manufacturer and ... men’s jackets; all these items are offered at extremely ...
Breaking Medicine News(10 mins):Health News:With New Semester Under Way, LunaDress Unveils The Most Fashionable Prom Dresses 2Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Cool Jackets Are For Sale At Fecbek.com 2
... MONDAY, May 4 (HealthDay News) -- Women may be ... according to a new study. , In an examination ... had been referred to a lung cancer center between ... tended to be younger when they developed the disease, ...
... Data Sharing Capabilities of PrimeSuite Enables Physicians to Make ... EssenceCARROLLTON, Ga., May 4 Greenway Medical Technologies continues ... point-of-care solutions that equip physicians with the tools necessary ... time is of the essence. Greenway,s recent participation in ...
... directly from worldwide headlines, Spike TV has begun production ... "Surviving Disaster" focused on how to survive a swine ... be shot in Los Angeles and no airdate has ... )In "Surviving Disaster," Spike TV presents a series ...
... and brand reflects regional vision for healthcare service ... and LANGHORNE, Pa., May 4 Frankford Hospital ... to Aria (pronounced ARE-EE-UH) Health. The decision ... at its existing hospital and outpatient locations comes ...
... The Monell Center announced today that it has received ... & Melinda Gates Foundation. The grant will support ... A. S. Breslin, PhD, titled "Taste-Guided Behavior on Mosquitoes ... of 81 grants announced by the Gates Foundation in ...
... is known to have a positive effect on maintaining a ... the Journal of Thoracic Oncology has shown that ... secondary prevention of cancer. The Journal of Thoracic Oncology ... the Study of Lung Cancer. Dr. Jennifer Temel at Massachusetts ...
Cached Medicine News:Health News:Smoking Packs a Tougher Wallop for Women 2Health News:Greenway Medical Technologies' PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care 2Health News:Greenway Medical Technologies' PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care 3Health News:Greenway Medical Technologies' PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care 4Health News:Spike TV Goes Into Production of Special Episode of Original Series 'Surviving Disaster' Focused on the Swine Flu and Other Pandemics 2Health News:Frankford Hospital Changes Its Name to Aria Health 2Health News:Monell Center receives $100,000 Grand Challenges Explorations grant 2
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Antigen-Antibody Pens-Using a proprietary and patented technology, ... pens, called Antigen-Antibody pens-TM, that will allow ... membranes in any form or shape or ... helps to see antigen being written on ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... 350 Liters of pure water, Complete, Compact ... Purified Water,Millipores compact S.D.S. Storage and Distribution ... 350 liters of purified water produced by ... consistent purity of stored water, provide effective ...
Medicine Products: